Home
About Us
Company News
Contact Us
Expanded Access Program
Home
About Us
Company News
Contact Us
Expanded Access Program
中文/EN
Company News
News
2025-11-07
Signet Therapeutics Wins BioTech Breakthrough Award For “Drug Discovery Innovation Award”
Learn More
2025-04-01
Preclinical Data on SIGX1094R, the First Targeted Therapy for Diffuse Gastric Cancer, to be Presented at AACR 2025
Learn More
2025-02-25
Expanded Access Policy
Learn More
2025-01-21
World’s First Potential Target Therapy for Diffuse Gastric Cancer Granted Fast Track Designation by the U.S. FDA
Learn More
2025-01-16
World’s First Drug Candidate developed by Organoid and AI Doses First Patient in Phase 1 Study for first Diffusive Gastric Cancer Targeted Therapy
Learn More
2024-12-03
Signet Therapeutics Raised Over 9 Million US Dollars in Pre-A Round Funding to Accelerate Clinical Trials and Drug Development
Learn More
2024-11-25
Signet Therapeutics Announces FDA Orphan Drug Designation (ODD) for SIGX1094R in Gastric Cancer Treatment
Learn More
2024-09-20
Signet Therapeutics' Targeted Therapy for Diffuse Gastric Cancer Receives IND Accelerated Approval by the NMPA
Learn More
2024-07-03
Signet Therapeutics Announces IND Approval by the FDA for World’s First Targeted Therapy for Diffuse Gastric Cancer
Learn More
1
2